Early-Stage Classic Hodgkin Lymphoma: The Utilization of Radiation Therapy and Its Impact on Overall Survival Presented in part at the 56th Annual Meeting of the American Society for Radiation Oncology, September 14-17, 2014, San Francisco, CA.

International Journal of Radiation Oncology Biology Physics

Volumn 93, Issue 3, 2015, Pages 684-693

  Parikh, Rahul R ^a   Grossbard, Michael L ^b   Harrison, Louis B ^c   Yahalom, Joachim ^d  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; HAZARDS; ONCOLOGY; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY; REGRESSION ANALYSIS;

CLINICAL FEATURES; CONFIDENCE INTERVAL; INITIAL TREATMENT; KAPLAN-MEIER METHOD; METHODS AND MATERIALS; PROPENSITY SCORE MATCHING; PROPORTIONAL HAZARDS; SOCIO-ECONOMIC STATUS;

PATIENT TREATMENT;

ADULT; CANCER CENTER; CANCER RADIOTHERAPY; CANCER STAGING; CLASSICAL HODGKIN LYMPHOMA; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; EDUCATION; FEMALE; HEALTH CARE UTILIZATION; HUMAN; INCOME; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICALLY UNINSURED; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOCIAL STATUS; AGE; AGED; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; HODGKIN DISEASE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; SOCIOECONOMICS; UTILIZATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 84942371478     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2015.06.039     Document Type: Conference Paper

References (32)

1. A. Engert, A. Plutschow, H.T. Eich, and et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma N Engl J Med 363 2010 640 652
2. C. Ferme, H. Eghbali, J.H. Meerwaldt, and et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease N Engl J Med 357 2007 1916 1927
3. M.V. Peters, and K.C. Middlemiss A study of Hodgkin's disease treated by irradiation Am J Roentgenol Radium Ther Nucl Med 79 1958 114 121
4. M.V. Maraldo, M.C. Aznar, I.R. Vogelius, and et al. Involved node radiation therapy: An effective alternative in early-stage Hodgkin lymphoma Int J Radiat Oncol Biol Phys 85 2013 1057 1065
5. J.M. Raemaekers, M.P. Andre, M. Federico, and et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial J Clin Oncol 32 2014 1188 1194
6. S. Laskar, T. Gupta, S. Vimal, and et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need? J Clin Oncol 22 2004 62 68
7. J.B. Nachman, R. Sposto, P. Herzog, and et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy J Clin Oncol 20 2002 3765 3771
8. D.J. Straus, C.S. Portlock, J. Qin, and et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIa nonbulky Hodgkin disease Blood 104 2004 3483 3489
9. C. Herbst, F.A. Rehan, C. Brillant, and et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: A systematic review Haematologica 95 2010 494 500
10. M. Koshy, S.E. Rich, U. Mahmood, and et al. Declining use of radiotherapy in stage I and II Hodgkin's disease and its effect on survival and secondary malignancies Int J Radiat Oncol Biol Phys 82 2012 619 625
11. A.J. Olszewski, R. Shrestha, and J.J. Castillo Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: Analysis of the national cancer data base J Clin Oncol 33 2015 625 633
12. R.M. Meyer, M.K. Gospodarowicz, J.M. Connors, and et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma N Engl J Med 366 2012 399 408
13. H.S. Park, C.P. Gross, D.V. Makarov, and et al. Immortal time bias: A frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy Int J Radiat Oncol Biol Phys 83 2012 1365 1373
14. D.B. Rubin Estimating causal effects from large data sets using propensity scores Ann Intern Med 127 1997 757 763
15. J. Yahalom Role of radiation therapy in Hodgkin's lymphoma Cancer J 15 2009 155 160
16. A.K. Ng, M.P. Bernardo, E. Weller, and et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger J Clin Oncol 20 2002 2101 2108
17. A. Aviles, and S. Delgado A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease Clin Lab Haematol 20 1998 95 99
18. R.M. Meyer, M.K. Gospodarowicz, J.M. Connors, and et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group J Clin Oncol 23 2005 4634 4642
19. G. Danaei, L.A. Rodriguez, O.F. Cantero, and et al. Observational data for comparative effectiveness research: An emulation of randomised trials of statins and primary prevention of coronary heart disease Stat Methods Med Res 22 2013 70 96
20. M.A. Hernan, A. Alonso, R. Logan, and et al. Observational studies analyzed like randomized experiments: An application to postmenopausal hormone therapy and coronary heart disease Epidemiology 19 2008 766 779
21. J. Radford, T. Illidge, N. Counsell, and et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma N Engl J Med 372 2015 1598 1607
22. D.J. Straus, J.L. Johnson, A.S. LaCasce, and et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: Pretreatment prognostic factors and interim PET Blood 117 2011 5314 5320
23. A. Engert, J. Franklin, H.T. Eich, and et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 trial J Clin Oncol 25 2007 3495 3502
24. E.M. Noordijk, J. Thomas, C. Ferme, and et al. First results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL) J Clin Oncol 23 June 1 Suppl 2005 6505
25. O.W. Press, M. LeBlanc, A.S. Lichter, and et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage Ia to IIa Hodgkin's disease J Clin Oncol 19 2001 4238 4244
26. S. Pavlovsky, M.T. Santarelli, F.S. Muriel, and et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III-IV a & b Hodgkin's disease Ann Oncol 3 1992 533 537
27. S. Arai, M. Fanale, S. DeVos, and et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant Leuk Lymphoma 54 2013 2531 2533
28. B.M. Aleman, A.W. van den Belt-Dusebout, W.J. Klokman, and et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease J Clin Oncol 21 2003 3431 3439
29. K.C. Oeffinger, A.C. Mertens, C.A. Sklar, and et al. Chronic health conditions in adult survivors of childhood cancer N Engl J Med 355 2006 1572 1582
30. J. Yahalom Don't throw out the baby with the bathwater: On optimizing cure and reducing toxicity in Hodgkin's lymphoma J Clin Oncol 24 2006 544 548
31. A. Engert, P. Schiller, A. Josting, and et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group J Clin Oncol 21 2003 3601 3608
32. L. Specht, J. Yahalom, T. Illidge, and et al. Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG) Int J Radiat Oncol Biol Phys 89 2014 854 862